Neuroendocrine Tumors (NET) & Other Radiosensitive Tumors | Virtual Congress

Disease Education

Disease Education Clinical Trials

.atomic-select.jsAtomicSelect { display: none; }

Disease Education

Disease Education Clinical Trials

Expression of Somatostatin Receptors on GEP-NET Cells

Explore Clinical Trials

NCT04711135

NETTER-P

A multicenter open-label study to evaluate safety and dosimetry of [177Lu]Lu-DOTA-TATE in adolescent patients with somatostatin receptor positive gastroenteropancreatic neuroendocrine (GEP-NET) tumors, pheochromocytomas and paragangliomas (PPGLs)

NCT05109728

GBM

A Phase Ib dose-finding study assessing safety and activity of [177Lu]Lu-DOTA-TATE in newly diagnosed glioblastoma (GBM) in combination with radiotherapy with or without temozolomide, and in recurrent GBM as a single agent

NCT05142696

SCLC

A phase Ib dose finding study assessing safety and activity of [177Lu]Lu-DOTA-TATE in newly diagnosed ES-SCLC in combination with carboplatin, etoposide, and tislelizumab in induction and with tislelizumab in maintenance treatment phase

Compound(s) are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established and there is no guarantee that they will become commercially available for the use(s) under investigation.

.lazy { display: none; }

Use of website is governed by the Terms of Use and Privacy Policy.

10/22 121333-3